Details

Autor(en) / Beteiligte

• Bartlett, Adam W
• Lumbiganon, Pagakrong
• Jamal Mohamed, Thahira A
• Lapphra, Keswadee
• Muktiarti, Dina
• Du, Quy Tuan
• Hansudewechakul, Rawiwan
• Ly, Penh Sun
• Truong, Khanh Huu
• Van Nguyen, Lam
• Puthanakit, Thanyawee
• Sudjaritruk, Tavitiya
• Chokephaibulkit, Kulkanya
• Do, Viet Chau
• Kumarasamy, Nagalingeswaran
• Nik Yusoff, Nik Khairulddin
• Kurniati, Nia
• Fong, Moy Siew
• Wati, Dewi Kumara
• Nallusamy, Revathy
• Sohn, Annette H
• Kariminia, Azar

Titel

Dual Analysis of Loss to Follow-up for Perinatally HIV-Infected Adolescents Receiving Combination Antiretroviral Therapy in Asia

Ist Teil von

• Journal of acquired immune deficiency syndromes (1999), 2019-12, Vol.82 (5), p.431

Ort / Verlag

United States

Erscheinungsjahr

2019

Quelle

MEDLINE

Beschreibungen/Notizen

• Perinatally HIV-infected adolescents (PHIVA) are an expanding population vulnerable to loss to follow-up (LTFU). Understanding the epidemiology and factors for LTFU is complicated by varying LTFU definitions. Asian regional cohort incorporating 16 pediatric HIV services across 6 countries. Data from PHIVA (aged 10-19 years) who received combination antiretroviral therapy 2007-2016 were used to analyze LTFU through (1) an International epidemiology Databases to Evaluate AIDS (IeDEA) method that determined LTFU as >90 days late for an estimated next scheduled appointment without returning to care and (2) the absence of patient-level data for >365 days before the last data transfer from clinic sites. Descriptive analyses and competing-risk survival and regression analyses were used to evaluate LTFU epidemiology and associated factors when analyzed using each method. Of 3509 included PHIVA, 275 (7.8%) met IeDEA and 149 (4.3%) met 365-day absence LTFU criteria. Cumulative incidence of LTFU was 19.9% and 11.8% using IeDEA and 365-day absence criteria, respectively. Risk factors for LTFU across both criteria included the following: age at combination antiretroviral therapy initiation <5 years compared with age ≥5 years, rural clinic settings compared with urban clinic settings, and high viral loads compared with undetectable viral loads. Age 10-14 years compared with age 15-19 years was another risk factor identified using 365-day absence criteria but not IeDEA LTFU criteria. Between 12% and 20% of PHIVA were determined LTFU with treatment fatigue and rural treatment settings consistent risk factors. Better tracking of adolescents is required to provide a definitive understanding of LTFU and optimize evidence-based models of care.